U.S. Markets closed

Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced that Laura Shawver, Ph.D., president and chief executive officer, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY. The presentation will begin at 2:30 p.m. ET on Thursday, February 28, 2019.

The live webcast of the company’s presentation will be available at Synthorx’s investor relations website. An archived replay will be available for 30 days following the presentation.

To receive Synthorx’s press releases and other investor information, please visit the Investor Relations page of the company’s website and register for email alerts.

About Synthorx
Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute. The company is headquartered in La Jolla, Calif. For more information, visit www.synthorx.com.

Investor Contacts:
Enoch Kariuki, Pharm.D.
Synthorx, Inc.
ekariuki@synthorx.com
858-750-4750

Christina Tartaglia
Stern Investor Relations
christina.tartaglia@sternir.com
212-362-1200

Media Relations Contact:
Lauren Fish
Canale Communications
lauren@canalecomm.com
619-849-5386